A Phase 1 interventional study of GSK3858279 IV and GSK3858279 SC in Pain, Inflammatory, sponsored by GlaxoSmithKline. Completed at 5 sites in 3 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-22.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Pain by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Pain · GlaxoSmithKline.
Among the 30 studies in Pain by GlaxoSmithKline, this one is the 11th largest by enrollment, is one of 2 that started in 2018, is one of 16 in phase 1, and was the 24th registered.
10,071 studies on the registry are indexed under Pain; 1,649 are open to participants now.
Browse Pain studies →None of the 30 studies in Pain by GlaxoSmithKline is open now. The open studies under Pain, anywhere →
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 97 is above the median of 66 across 8,507 interventional studies indexed under Pain.
Median enrollment 35 across the 30 interventional studies. Of the 30 that completed or were terminated, 15 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 30 studies in Pain by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is the first administration of GSK3858279 in humans and will be conducted in two parts: Part A will consist of a single ascending dose escalation design to evaluate safety, tolerability, PK, TE and immunogenicity of either a single intravenous (IV) or a single subcutaneous (SC) dose. Approximately 48 healthy participants will be enrolled in 6 cohorts and randomized to 3:1 ratio (GSK3858279 or placebo). Part B will evaluate safety, tolerability, efficacy (pain), PK, TE and immunogenicity after repeat SC dosing. Approximately 50 OA participants will be randomized in a parallel group design to receive either GSK3858279 or placebo in a 1:1 ratio.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Part A:
For Part B:
Exclusion Criteria:
For Part A:
For Part B:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible participants will receive GSK3858279 via IV route.
Drug: GSK3858279 IV
Eligible participants will receive GSK3858279 via IV route.
Drug: GSK3858279 IV
Eligible participants will receive GSK3858279 via IV route.
Drug: GSK3858279 IV
Eligible participants will receive GSK3858279 via IV route.
Drug: GSK3858279 IV
Eligible participants will receive GSK3858279 via IV route.
Drug: GSK3858279 IV
Eligible participants will receive GSK3858279 via SC route.
Drug: GSK3858279 SC
Eligible participants will receive placebo matching to GSK3858279 via SC or IV route.
Drug: Placebo matching to GSK3858279 (SC or IV)
Eligible participants will receive GSK3858279 via SC route.
Drug: GSK3858279 SC
Eligible participants will receive placebo matching to GSK3858279 via SC route.
Drug: Placebo matching to GSK3858279 (SC)
GSK3858279 will be available as solution for injection to be administered via IV route.
GSK3858279 will be available as solution for injection to be administered via SC route.
Placebo will be available as sodium chloride solution to be administered via SC or IV route.
Placebo will be available as sodium chloride solution to be administered via SC route.
Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. TEAE is defined as an AE that occurred on or after the first dose date of study intervention. SAEs is defined as any serious adverse event that, at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, other situations as per investigator's medical or scientific judgment.
Time frame: Up to 141 days
Part B: Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. TEAE is defined as an AE that occurred on or after the first dose date of study intervention. SAEs is defined as any serious adverse event that, at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, other situations as per investigator's medical or scientific judgment.
Time frame: Up to 141 days
Part A: Number of Participants With Clinically Significant Changes in Hematology, Clinical Chemistry Laboratory Parameters and Urinalysis
The parameters evaluated for Hematology were Basophils, Eosinophils, Hematocrit, Hemoglobin (Hg), Lymphocytes, mean corpuscular Hg, mean corpuscular volume, Monocytes, Platelet count, Red blood cells, Reticulocytes, Total Neutrophils, White blood cells count (WBC). For Clinical Chemistry- Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Bilirubin, Calcium, Creatinine, Direct bilirubin, Glucose, Potassium, Sodium, Total bilirubin, Total protein, TroponinT, N-terminal pro B-type natriuretic peptide (NT-ProBNP) and Urea. For Urinalysis-Urine bilirubin, Occult blood, Glucose, Ketones, Nitrates, pH, Protein, Specific gravity, Urobilinogen and Leukocyte Esterase for detecting WBC. Changes from baseline in hematology, clinical chemistry and urinalysis were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.
Time frame: Up to 141 days
Part B: Number of Participants With Clinically Significant Changes in Hematology, Clinical Chemistry Laboratory Parameters and Urinalysis
The parameters evaluated for Hematology were Basophils, Eosinophils, Hematocrit, Hemoglobin (Hg), Lymphocytes, mean corpuscular Hg, mean corpuscular volume, Monocytes, Platelet count, Red blood cells, Reticulocytes, Total Neutrophils, White blood cells count (WBC). For Clinical Chemistry- Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Bilirubin, Calcium, Creatinine, Direct bilirubin, Glucose, Potassium, Sodium, Total bilirubin, Total protein, TroponinT, N-terminal pro B-type natriuretic peptide (NT-ProBNP) and Urea. For Urinalysis-Urine bilirubin, Occult blood, Glucose, Ketones, Nitrates, pH, Protein, Specific gravity, Urobilinogen and Leukocyte Esterase for detecting WBC. Changes from baseline in hematology, clinical chemistry and urinalysis were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.
Time frame: Up to 141 days
Part A: Number of Participants With Clinically Significant Changes in Electrocardiogram Findings
Twelve-lead Electrocardiogram (ECG) were performed in a semi-supine position using an ECG machine that automatically calculates the heart rate and measures PR interval, QRS duration, Uncorrected QT and corrected QT intervals (QTc) intervals. Changes from baseline in ECG findings were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.
Time frame: Up to 141 days
Part B: Number of Participants With Clinically Significant Changes in Electrocardiogram Findings
Twelve-lead Electrocardiogram (ECG) were performed in a semi-supine position using an ECG machine that automatically calculates the heart rate and measures PR interval, QRS duration, Uncorrected QT and corrected QT intervals (QTc) intervals. Changes from baseline in ECG findings were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.
Time frame: Up to 141 days
Part A: Number of Participants With Clinically Significant Changes in Vital Signs
Vital signs included systolic and diastolic blood pressure, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Temperature was also measured as a vital sign but did not require positioning or rest prior to measuring. Changes from baseline in vital signs were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.
Time frame: Up to 141 days
Part B: Number of Participants With Clinically Significant Changes in Vital Signs
Vital signs included systolic and diastolic blood pressure, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Temperature was also measured as a vital sign but did not require positioning or rest prior to measuring. Changes from baseline in vital signs were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.
Time frame: Up to 141 days
Part B: Change From Baseline in Knee Pain as Assessed by Average of Daily Pain Numeric Rating Scale at Week 8
Change from Baseline in knee pain due to Osteoarthritis were reported by average of daily pain numeric rating scale (NRS) at Week 8. The pain NRS is an 11-point scale (ranging from 0-10) for self-reporting of average knee pain where 0 indicates no pain, and 10 indicates the worst possible pain. For each participant, the mean pain score prior to each visit was calculated as the average pain intensity in the 7 days prior to assessment visit. Participants were instructed to complete the pain NRS questionnaire at approximately the same time each day. A negative value change from baseline indicates an improvement. Baseline scores for each participant were assigned based on the first dosing visit.
Time frame: Baseline (Day 1) and Week 8
Part B: Change From Baseline in Worst Knee Pain Intensity as Assessed by Numeric Rating Scale at Week 8
Change from Baseline in worst knee pain intensity were assessed using NRS at Week 8. The pain NRS is an 11-point scale (ranging from 0-10) for self-reporting of average knee pain where 0 indicated no pain, and 10 indicated worst possible pain. The mean pain score prior to each visit was calculated as the average pain intensity in the 7 days prior to assessment visit. Participants were instructed to complete the pain NRS questionnaire at approximately the same time each day. A negative value change from baseline indicates an improvement. Baseline scores for each participant were assigned based on the first dosing visit.
Time frame: Baseline (Day 1) and Week 8
Part A: Serum Concentrations of GSK3858279 Following a Single IV Dose
Time frame: Up to 141 days
Part A: Serum Concentrations of GSK3858279 Following a Single SC Dose
Time frame: Up to 141 days
Part B: Serum Concentration of GSK3858279 Following Repeat SC Dose
Time frame: Up to 141 days
Part A: Area Under the Time-Concentration Curve (AUC) Over the Dosing Interval (0-tau) (AUC[0-tau]) Following a Single IV Dose of GSK3858279
Time frame: Up to 141 days
Part A: AUC From Zero to Time t (0-t) (AUC[0-t]) Following a Single IV Dose of GSK3858279
Time frame: Up to 141 days
Part A: AUC From Zero to Infinity (0-infinity) (AUC[0-infinity]) Following a Single IV Dose of GSK3858279
Time frame: Up to 141 days
Part A: AUC(0-tau) Following a Single SC Dose of GSK3858279
Time frame: Up to 141 days
Part A: AUC From Zero to Time t (0-t) (AUC[0-t]) Following a Single SC Dose of GSK3858279
Time frame: Up to 141 days
Part A: AUC From Zero to Infinity (0-infinity) (AUC[0-infinity]) Following a Single SC Dose of GSK3858279
Time frame: Up to 141 days
Part B: AUC(0-tau) Following a Repeat SC Dose of GSK3858279
Time frame: Baseline and Week 8
Part B: AUC(0-t) Following a Repeat SC Dose of GSK3858279
Time frame: Up to 141 days
Part B: AUC(0-infinity) Following a Repeat SC Dose of GSK3858279
Time frame: Up to 141 days
Part A: Maximum Concentration (Cmax) After a Single IV Dose of GSK3858279
Time frame: Up to 141 days
Part A: Maximum Concentration (Cmax) After a Single SC Dose of GSK3858279
Time frame: Up to 141 days
Part B: Cmax After Repeat SC Dose of GSK3858279
Time frame: Baseline and Week 8
Part A: Half-life (t1/2) Following a Single IV Dose of GSK3858279
Time frame: Up to 141 days
Part A: Half-life (t1/2) Following a Single SC Dose of GSK3858279
Time frame: Up to 141 days
Part B: t1/2 Following a Repeat SC Dose of GSK3858279
Time frame: Up to 141 days
Part A: Clearance (CL) Following a Single IV Dose of GSK3858279
Time frame: Up to 141 days
Part A: Clearance (CL) Following a Single SC Dose of GSK3858279
Time frame: Up to 141 days
Part B: CL Following a Repeat SC Dose of GSK3858279
Time frame: Up to 141 days
Part A: Volume of Distribution at Steady State (Vss) Following a Single IV Dose of GSK3858279
Time frame: Up to 141 days
Part A: Volume of Distribution at Steady State (Vss) Following a Single SC Dose of GSK3858279
Time frame: Up to 141 days
Part B: Vss Following a Repeat SC Dose of GSK3858279
Time frame: Up to 141 days
Part A: Volume of Distribution (V) Following a Single IV Dose of GSK3858279
Time frame: Up to 141 days
Part A: Volume of Distribution (V) Following a Single SC Dose of GSK3858279
Time frame: Up to 141 days
Part B: Volume of Distribution (V) Following a Repeat SC Dose of GSK3858279
Time frame: Up to 141 days
Part A: Free Chemokine Ligand 17 (CCL17) Levels in Serum Following Single IV Dose of GSK3858279
Time frame: Up to 141 days
Part A: CCL17 Levels in Serum Following Single SC Dose of GSK3858279
Time frame: Up to 141 days
Part B: Free CCL17 Levels in Serum Following Repeat SC Dose of GSK3858279
Time frame: Up to 141 days
Part A: Total CCL17 Levels in Serum Following Single IV Dose of GSK3858279
Time frame: Up to 141 days
Part A: Total CCL17 Levels in Serum Following Single SC Dose of GSK3858279
Time frame: Up to 141 days
Part B: Total CCL17 Levels in Serum Following Repeat SC Dose of GSK3858279
Time frame: Up to 141 days
This was a 2-part study. Part A was a sequential group with a single ascending dose escalation in healthy participants. Single intravenous (IV) doses and a single subcutaneous (SC) dose were investigated in separate cohorts of participants. Part B was parallel group with repeat SC dosing of GSK3858279 or matching placebo in participants with Knee Osteoarthritis.
| Milestone | Part A: Cohort 1: GSK3858279 | Part A: Cohort 2: GSK3858279 | Part A: Cohort 3: GSK3858279 | Part A: Cohort 4: GSK3858279 | Part A: Cohort 5: GSK3858279 | Part A: Cohort 6: GSK3858279 | Part A: Pooled Placebo | Part B: Cohort 7: GSK3858279 | Part B: Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 6 | 13 | 24 | 24 |
| Completed | 6 | 6 | 6 | 5 | 6 | 6 | 12 | 24 | 24 |
| Not completed | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. TEAE is defined as an AE that occurred on or after the first dose date of study intervention. SAEs is defined as any serious adverse event that, at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, other situations as per investigator's medical or scientific judgment.
| Participants | Part A: Cohort 1: GSK3858279 | Part A: Cohort 2: GSK3858279 | Part A: Cohort 3: GSK3858279 | Part A: Cohort 4: GSK3858279 | Part A: Cohort 5: GSK3858279 | Part A: Cohort 6: GSK3858279 | Part A: Pooled Placebo |
|---|---|---|---|---|---|---|---|
| Participants with TEAEs | 2 | 2 | 4 | 6 | 6 | 6 | 12 |
| Participants with SAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. TEAE is defined as an AE that occurred on or after the first dose date of study intervention. SAEs is defined as any serious adverse event that, at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, other situations as per investigator's medical or scientific judgment.
| Participants | Part B: Cohort 7: GSK3858279 | Part B: Placebo |
|---|---|---|
| Participants with TEAEs | 21 | 15 |
| Participants with SAEs | 0 | 0 |
The parameters evaluated for Hematology were Basophils, Eosinophils, Hematocrit, Hemoglobin (Hg), Lymphocytes, mean corpuscular Hg, mean corpuscular volume, Monocytes, Platelet count, Red blood cells, Reticulocytes, Total Neutrophils, White blood cells count (WBC). For Clinical Chemistry- Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Bilirubin, Calcium, Creatinine, Direct bilirubin, Glucose, Potassium, Sodium, Total bilirubin, Total protein, TroponinT, N-terminal pro B-type natriuretic peptide (NT-ProBNP) and Urea. For Urinalysis-Urine bilirubin, Occult blood, Glucose, Ketones, Nitrates, pH, Protein, Specific gravity, Urobilinogen and Leukocyte Esterase for detecting WBC. Changes from baseline in hematology, clinical chemistry and urinalysis were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.
| Participants | Part A: Cohort 1: GSK3858279 | Part A: Cohort 2: GSK3858279 | Part A: Cohort 3: GSK3858279 | Part A: Cohort 4: GSK3858279 | Part A: Cohort 5: GSK3858279 | Part A: Cohort 6: GSK3858279 | Part A: Pooled Placebo |
|---|---|---|---|---|---|---|---|
| Hematology | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Clinical Chemistry | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urinalysis | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The parameters evaluated for Hematology were Basophils, Eosinophils, Hematocrit, Hemoglobin (Hg), Lymphocytes, mean corpuscular Hg, mean corpuscular volume, Monocytes, Platelet count, Red blood cells, Reticulocytes, Total Neutrophils, White blood cells count (WBC). For Clinical Chemistry- Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Bilirubin, Calcium, Creatinine, Direct bilirubin, Glucose, Potassium, Sodium, Total bilirubin, Total protein, TroponinT, N-terminal pro B-type natriuretic peptide (NT-ProBNP) and Urea. For Urinalysis-Urine bilirubin, Occult blood, Glucose, Ketones, Nitrates, pH, Protein, Specific gravity, Urobilinogen and Leukocyte Esterase for detecting WBC. Changes from baseline in hematology, clinical chemistry and urinalysis were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.
| Participants | Part B: Cohort 7: GSK3858279 | Part B: Placebo |
|---|---|---|
| Hematology | 0 | 0 |
| Clinical Chemistry | 0 | 0 |
| Urinalysis | 0 | 0 |
Twelve-lead Electrocardiogram (ECG) were performed in a semi-supine position using an ECG machine that automatically calculates the heart rate and measures PR interval, QRS duration, Uncorrected QT and corrected QT intervals (QTc) intervals. Changes from baseline in ECG findings were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.
| Participants | Part A: Cohort 1: GSK3858279 | Part A: Cohort 2: GSK3858279 | Part A: Cohort 3: GSK3858279 | Part A: Cohort 4: GSK3858279 | Part A: Cohort 5: GSK3858279 | Part A: Cohort 6: GSK3858279 | Part A: Pooled Placebo |
|---|---|---|---|---|---|---|---|
| Part A: Number of Participants With Clinically Significant Changes in Electrocardiogram Findings | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Twelve-lead Electrocardiogram (ECG) were performed in a semi-supine position using an ECG machine that automatically calculates the heart rate and measures PR interval, QRS duration, Uncorrected QT and corrected QT intervals (QTc) intervals. Changes from baseline in ECG findings were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.
| Participants | Part B: Cohort 7: GSK3858279 | Part B: Placebo |
|---|---|---|
| Part B: Number of Participants With Clinically Significant Changes in Electrocardiogram Findings | 0 | 0 |
Vital signs included systolic and diastolic blood pressure, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Temperature was also measured as a vital sign but did not require positioning or rest prior to measuring. Changes from baseline in vital signs were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.
| Participants | Part A: Cohort 1: GSK3858279 | Part A: Cohort 2: GSK3858279 | Part A: Cohort 3: GSK3858279 | Part A: Cohort 4: GSK3858279 | Part A: Cohort 5: GSK3858279 | Part A: Cohort 6: GSK3858279 | Part A: Pooled Placebo |
|---|---|---|---|---|---|---|---|
| Part A: Number of Participants With Clinically Significant Changes in Vital Signs | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Vital signs included systolic and diastolic blood pressure, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Temperature was also measured as a vital sign but did not require positioning or rest prior to measuring. Changes from baseline in vital signs were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.
| Participants | Part B: Cohort 7: GSK3858279 | Part B: Placebo |
|---|---|---|
| Part B: Number of Participants With Clinically Significant Changes in Vital Signs | 0 | 0 |
Change from Baseline in knee pain due to Osteoarthritis were reported by average of daily pain numeric rating scale (NRS) at Week 8. The pain NRS is an 11-point scale (ranging from 0-10) for self-reporting of average knee pain where 0 indicates no pain, and 10 indicates the worst possible pain. For each participant, the mean pain score prior to each visit was calculated as the average pain intensity in the 7 days prior to assessment visit. Participants were instructed to complete the pain NRS questionnaire at approximately the same time each day. A negative value change from baseline indicates an improvement. Baseline scores for each participant were assigned based on the first dosing visit.
| Scores on a scale | Part B: Cohort 7: GSK3858279 | Part B: Placebo |
|---|---|---|
| Part B: Change From Baseline in Knee Pain as Assessed by Average of Daily Pain Numeric Rating Scale at Week 8 | -2.82 ± 1.752 | -1.62 ± 1.709 |
Change from Baseline in worst knee pain intensity were assessed using NRS at Week 8. The pain NRS is an 11-point scale (ranging from 0-10) for self-reporting of average knee pain where 0 indicated no pain, and 10 indicated worst possible pain. The mean pain score prior to each visit was calculated as the average pain intensity in the 7 days prior to assessment visit. Participants were instructed to complete the pain NRS questionnaire at approximately the same time each day. A negative value change from baseline indicates an improvement. Baseline scores for each participant were assigned based on the first dosing visit.
| Scores on a scale | Part B: Cohort 7: GSK3858279 | Part B: Placebo |
|---|---|---|
| Part B: Change From Baseline in Worst Knee Pain Intensity as Assessed by Numeric Rating Scale at Week 8 | -2.89 ± 2.185 | -1.58 ± 2.057 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over Part A and Part B: Up to 141 Days. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Cohort 1: GSK3858279 | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part A: Cohort 2: GSK3858279 | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part A: Cohort 3: GSK3858279 | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part A: Cohort 4: GSK3858279 | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part A: Cohort 5: GSK3858279 | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part A: Cohort 6: GSK3858279 | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part A: Pooled Placebo | 0/13 (0%) | 0/13 (0%) | 12/13 (92.3%) |
| Part B: Cohort 7: GSK3858279 | 0/24 (0%) | 0/24 (0%) | 21/24 (87.5%) |
| Part B: Placebo | 0/24 (0%) | 0/24 (0%) | 15/24 (62.5%) |
| Event | Part A: Cohort 1: GSK3858279 | Part A: Cohort 2: GSK3858279 | Part A: Cohort 3: GSK3858279 | Part A: Cohort 4: GSK3858279 | Part A: Cohort 5: GSK3858279 | Part A: Cohort 6: GSK3858279 | Part A: Pooled Placebo | Part B: Cohort 7: GSK3858279 | Part B: Placebo |
|---|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 0/6 | 0/6 | 0/6 | 3/6 | 1/6 | 3/6 | 3/13 | 3/24 | 2/24 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/6 | 0/6 | 1/6 | 3/6 | 1/6 | 1/6 | 2/13 | 2/24 | 0/24 |
| DiarrhoeaGastrointestinal disorders | 1/6 | 0/6 | 0/6 | 2/6 | 0/6 | 0/6 | 1/13 | 2/24 | 0/24 |
| Catheter site bruiseGeneral disorders | 0/6 | 0/6 | 0/6 | 0/6 | 2/6 | 0/6 | 1/13 | 0/24 | 0/24 |
| Skin lacerationInjury, poisoning and procedural complications | 0/6 | 0/6 | 0/6 | 0/6 | 2/6 | 0/6 | 0/13 | 0/24 | 0/24 |
| HeadacheNervous system disorders | 0/6 | 0/6 | 0/6 | 2/6 | 1/6 | 1/6 | 3/13 | 2/24 | 5/24 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 2/6 | 1/13 | 0/24 | 0/24 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 2/6 | 2/13 | 0/24 | 0/24 |
| Eye irritationEye disorders | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/13 | 0/24 | 0/24 |
| Abdominal pain upperGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/13 | 1/24 | 1/24 |
| Age, Categorical(Participants) | Part A: Cohort 1: GSK3858279 | Part A: Cohort 2: GSK3858279 | Part A: Cohort 3: GSK3858279 | Part A: Cohort 4: GSK3858279 | Part A: Cohort 5: GSK3858279 | Part A: Cohort 6: GSK3858279 | Part A: Pooled Placebo | Part B: Cohort 7: GSK3858279 | Part B: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 6 | 5 | 6 | 6 | 6 | 13 | 17 | 18 | 83 |
| >=65 years | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 7 | 6 | 14 |
| Sex: Female, Male(Participants) | Part A: Cohort 1: GSK3858279 | Part A: Cohort 2: GSK3858279 | Part A: Cohort 3: GSK3858279 | Part A: Cohort 4: GSK3858279 | Part A: Cohort 5: GSK3858279 | Part A: Cohort 6: GSK3858279 | Part A: Pooled Placebo | Part B: Cohort 7: GSK3858279 | Part B: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 0 | 2 | 0 | 1 | 2 | 0 | 8 | 13 | 27 |
| Male | 5 | 6 | 4 | 6 | 5 | 4 | 13 | 16 | 11 | 70 |
| Race/Ethnicity, Customized(Participants) | Part A: Cohort 1: GSK3858279 | Part A: Cohort 2: GSK3858279 | Part A: Cohort 3: GSK3858279 | Part A: Cohort 4: GSK3858279 | Part A: Cohort 5: GSK3858279 | Part A: Cohort 6: GSK3858279 | Part A: Pooled Placebo | Part B: Cohort 7: GSK3858279 | Part B: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| ASIAN | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 4 |
| BLACK OR AFRICAN AMERICAN | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| WHITE | 6 | 5 | 6 | 4 | 5 | 6 | 13 | 23 | 24 | 92 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2018 to primary completion in Sep 2022, 51 months.
Results were first posted in Mar 2024, 1 year 6 months after primary completion.
Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 51 months is above that.
Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denrakibart